Table 1.

Phase III clinical trial involving FRα-targeted therapies.

Farlatuzumab
Title	Patients	Results	Reference
Randomized, double-blind, placebo-controlled, phase III study to assess the efficacy and safety of weekly MORAb-003 in combination with carboplatin and taxane in subjects with platinum-sensitive ovarian cancer in first relapse (MORAb-003-004; NCT00849667)	Platinum-sensitive EOC (1100 patients) in first relapse	No significant differences in PFS among the treatment arms were observed. The primary end point of PFS was not met.	[116,118]
Phase III randomized clinical trial of weekly paclitaxel with or without farletuzumab (MORAb-003-003; NCT00738699)	Platinum-resistant ovarian cancer (417 patients)	Study was terminated due to failure to meet pre-specified criteria.	[117]
Vintafolide (EC145)
Study for women with platinum resistant ovarian cancer evaluating EC145 in combination with Doxil® (PROCEED) (EC-FV-06; NCT01170650)	FRα-positive platinum-resistant ovarian cancer (640 patients)	Trial was terminated owing to failure to meet pre-specified PFS criteria.	[125]
Mirvetuximab soravtansine
Phase III RCT (FORWARD I) evaluating chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) vs. mirvetuximab soravtansine (IMGN853-0403; NCT02631876)	FRα-positive platinum-resistant ovarian cancer (366 patients)	Mirvetuximab soravtansine did not result in a significant improvement in PFS compared with chemotherapy.	[121]